Toronto, ON, April 15, 2019 – panCELLa Inc announced today that Dr. Andras Nagy, President & CSO, will present at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean will bring together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, the program will feature expert-led panels, extensive one-on-one partnering capabilities, and exclusive networking opportunities.
The meeting will feature presentations by 50+ leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as 35+ panelists and featured speakers.
The following are specific details regarding panCELLa Inc.’s presentation at the conference:
Event: 2019 Cell & Gene Meeting on the Mediterranean
Date: 24 April 2019
Time: 9:45 am (CEST) 3:45 am (EDT)
Location: Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, Spain
A live video webcast of all company presentations will be available at: http://www.meetingonthemed.com/webcast http://www.meetingonthemesa.com/webcast/and will also be published on the conference website shortly after the event.
Incorporated in August 2015, panCELLa (www.pancella.com) was founded by Dr. Andras Nagy and Dr. Armand Keating based on Dr. Nagy’s ground-breaking work in the area of stem cell research. Through panCELLa, Drs. Keating and Nagy are seeking to create an effective cell therapy derived from stem cells, which are modified to provide a sufficient and very high level of safety before and after the cells are introduced to the patient. Cell therapies with proliferating and in vitro expanded cells pose safety risks to patients. panCELLa offers technological solutions to this challenge – FailSafeTM and induced Allogeneic Cell Tolerance (iACT Stealth CellsTM ). panCELLa seeks to create universal “off the shelf” FailSafeTM Cells and to assist the pharmaceutical and biotechnology sectors to achieve such with their own cell lines. With FailSafeTM and iACT Stealth CellsTM, panCELLa seeks to provide a global cell line that will be safe for all humankind. Targeted medical applications include deadly, debilitating, or aggressive diseases requiring immediate treatment where there is no time to cultivate a customized stem cell treatment from the patient (i.e. cancer, cardiac infarct, stroke and spinal cord injury).
For further information, please contact Lisa Schummer via email email@example.com or phone (888) 613-6862
# # #